SillaJen
215600.KQ
1.73 USD
-0.02
-1.14%
s
Overview
Last close
1.73 usd
Market cap
237.73M usd
52 week high
4.93 usd
52 week low
1.65 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
281.906
Price/Book Value
2.4834
Enterprise Value
152.98M usd
EV/Revenue
179.6096
EV/EBITDA
-23.7838
Key financials
Revenue TTM
851740.54 usd
Gross Profit TTM
-867946.23 usd
EBITDA TTM
-16.87M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
123.36M usd
Net debt
N/A usd
About
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
- Symbol215600.KQ
- ExchangeKQ
- IsinKR7215600008
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CEODr. Eun-Sang Moon D.D.S., DDS, M.D.
- HeadquarterSeoul
- Web sitehttps://www.sillajen.com
